I-Mab ADR (IMAB)

$2.11 -0.01 (-0.47%)
Market Cap 173.12M
Revenue (ttm) 0.00
Net Income (ttm) -22.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 105,900
Avg Vol 643,684
Day's Range N/A - N/A
Shares Out 81.66M
Stochastic %K 42%
Beta 1.40
Analysts Strong Sell
Price Target $5.75

Company Profile

I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to resear...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 745 6330
Address:
2440 Research Boulevard, Suite 400, Rockville, United States
Chomo
Chomo Jul. 24 at 12:46 AM
$IMAB very tight but not volume at all
0 · Reply
Alexsandrab85
Alexsandrab85 Jul. 21 at 8:49 PM
$IMAB still holding 500 shares for dear
0 · Reply
Stocksman45
Stocksman45 Jul. 19 at 5:05 PM
$IMAB Complete Ownership? Thats great. I though biolabs had a piece of it. Next trial results has been moved up a couple of months to Q1 2026. With complete ownership, IMAB is a much more valuable target for aquisition or partnerships. "The deal structure is notably favorable - an upfront payment of only $1.8 million with $1.2 million in non-contingent payments through 2027, plus potential milestone payments up to $3.875 million. This represents a relatively modest investment to secure complete ownership of intellectual property that could become substantially more valuable if givastomig continues to show promising clinical results."
0 · Reply
Stocksman45
Stocksman45 Jul. 19 at 2:41 AM
$IMAB Bold positive move. Results of next trial sooner. All good. https://finance.yahoo.com/news/mab-strengthens-givastomig-intellectual-property-110000252.html
1 · Reply
jParkz
jParkz Jul. 15 at 12:30 AM
News out I-Mab to Present at the BTIG Virtual Biotechnology Conference https://marketwirenews.com/news-releases/i-mab-to-present-at-the-btig-virtual-biotechnology-c-6007643620724269.html $IMAB
0 · Reply
serfi
serfi Jul. 10 at 8:18 PM
$IMAB this is going to zero?
2 · Reply
JarvisFlow
JarvisFlow Jul. 9 at 11:00 AM
HC Wainwright & Co. updates rating for I-MAB ( $IMAB ) to Buy, target set at 7.
2 · Reply
JarvisFlow
JarvisFlow Jul. 9 at 11:00 AM
Needham updates rating for I-MAB ( $IMAB ) to Buy, target set at 5.
0 · Reply
LegendaryCharts
LegendaryCharts Jul. 9 at 9:34 AM
What is happening to APLM right now?! Seems like volume could be shifting in to APLM! This could be the next multi - day runner! APLM moves like a true nano nano floater! Show me some 50K buying candles and this could HALT UP and spike to 15+$ Some will buy now some will chase later! $NAOV $AUUD $IMAB $SNPX Update loading .
0 · Reply
Szilis793
Szilis793 Jul. 8 at 5:02 PM
$IMAB Exciting news ahead — a big breakthrough is coming soon for IMAB
1 · Reply
Latest News on IMAB
I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health

Jul 17, 2025, 7:00 AM EDT - 9 days ago

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

Jul 2, 2025, 11:15 AM EDT - 24 days ago

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research

Jun 30, 2025, 4:01 PM EDT - 26 days ago

I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

Jun 26, 2025, 6:30 AM EDT - 4 weeks ago

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

I-Mab to Present at Jefferies Global Healthcare Conference

May 20, 2025, 7:00 AM EDT - 2 months ago

I-Mab to Present at Jefferies Global Healthcare Conference

I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Mar 21, 2025, 4:30 PM EDT - 4 months ago

I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

I-Mab Announces Accelerated Givastomig Phase 1b Study Progress

Mar 7, 2025, 7:00 AM EST - 5 months ago

I-Mab Announces Accelerated Givastomig Phase 1b Study Progress

I-Mab to Participate in Leerink Partners Global Healthcare Conference

Feb 18, 2025, 7:00 AM EST - 5 months ago

I-Mab to Participate in Leerink Partners Global Healthcare Conference

I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:30 AM EST - 6 months ago

I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member

Jan 8, 2025, 7:00 AM EST - 7 months ago

I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

Jan 6, 2025, 7:00 AM EST - 7 months ago

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

I-Mab to Participate at the Piper Sandler Healthcare Conference

Nov 21, 2024, 7:00 AM EST - 8 months ago

I-Mab to Participate at the Piper Sandler Healthcare Conference

I-Mab Reports Third Quarter 2024 Results

Nov 14, 2024, 7:00 AM EST - 9 months ago

I-Mab Reports Third Quarter 2024 Results

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

Nov 6, 2024, 7:00 AM EST - 9 months ago

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

Oct 31, 2024, 7:00 AM EDT - 9 months ago

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

Oct 30, 2024, 7:00 AM EDT - 9 months ago

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

I-Mab to Participate at the Truist Securities BioPharma Symposium

Oct 28, 2024, 7:00 AM EDT - 9 months ago

I-Mab to Participate at the Truist Securities BioPharma Symposium

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

Sep 16, 2024, 4:01 PM EDT - 11 months ago

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer

Sep 10, 2024, 7:00 AM EDT - 11 months ago

I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer

I-MAB (IMAB) Q2 2024 Earnings Call Transcript

Aug 28, 2024, 11:50 AM EDT - 11 months ago

I-MAB (IMAB) Q2 2024 Earnings Call Transcript

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

Aug 28, 2024, 7:00 AM EDT - 11 months ago

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 7:00 AM EDT - 11 months ago

I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

I-Mab to Release 1H 2024 Financial Results on August 28, 2024

Aug 14, 2024, 7:00 AM EDT - 1 year ago

I-Mab to Release 1H 2024 Financial Results on August 28, 2024

I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)

Aug 7, 2024, 7:00 AM EDT - 1 year ago

I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)

I-Mab Announces Leadership Transitions

Jul 15, 2024, 7:30 AM EDT - 1 year ago

I-Mab Announces Leadership Transitions

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

Jun 5, 2024, 7:00 AM EDT - 1 year ago

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

BMY

I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

May 23, 2024, 5:05 PM EDT - 1 year ago

I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

I-Mab to Participate at the Jefferies Global Healthcare Conference

May 22, 2024, 7:00 AM EDT - 1 year ago

I-Mab to Participate at the Jefferies Global Healthcare Conference

I-MAB Filed 2023 Annual Report on Form 20-F

Apr 30, 2024, 7:00 AM EDT - 1 year ago

I-MAB Filed 2023 Annual Report on Form 20-F

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

Apr 5, 2024, 7:00 AM EDT - 1 year ago

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

I-Mab Announces Closing of the Divestiture of Business Operations in China

Apr 2, 2024, 4:01 PM EDT - 1 year ago

I-Mab Announces Closing of the Divestiture of Business Operations in China

I-Mab Reports Full Year 2023 Financial Results and Business Update

Mar 14, 2024, 5:00 PM EDT - 1 year ago

I-Mab Reports Full Year 2023 Financial Results and Business Update

I-Mab: Trading Below Net Cash With Multiple Upside Options

Feb 18, 2024, 3:28 AM EST - 1 year ago

I-Mab: Trading Below Net Cash With Multiple Upside Options

Biotech firm I-Mab to divest China operations, shift focus to US

Feb 7, 2024, 8:36 AM EST - 1 year ago

Biotech firm I-Mab to divest China operations, shift focus to US

I-Mab Signs Agreement to Divest its Assets and Business Operations in China

Feb 7, 2024, 6:00 AM EST - 1 year ago

I-Mab Signs Agreement to Divest its Assets and Business Operations in China

I-Mab Announces Participation at Jefferies and Piper Conferences in November

Nov 6, 2023, 8:00 AM EST - 1 year ago

I-Mab Announces Participation at Jefferies and Piper Conferences in November

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

Nov 2, 2023, 8:00 AM EDT - 1 year ago

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

Nov 1, 2023, 8:00 AM EDT - 1 year ago

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

Oct 16, 2023, 8:00 AM EDT - 1 year ago

I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503

Oct 10, 2023, 8:00 AM EDT - 1 year ago

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503

AbbVie terminates deal with I-Mab to develop cancer drug

Sep 22, 2023, 5:09 PM EDT - 2 years ago

AbbVie terminates deal with I-Mab to develop cancer drug

ABBV

I-Mab: Why This Company Trades At A Third The Value Of Its Cash

Sep 13, 2023, 4:59 PM EDT - 2 years ago

I-Mab: Why This Company Trades At A Third The Value Of Its Cash

I-Mab Announces Upcoming Participation at September Conferences

Sep 5, 2023, 8:00 AM EDT - 2 years ago

I-Mab Announces Upcoming Participation at September Conferences

I-Mab (IMAB) Q2 2023 Earnings Call Transcript

Aug 17, 2023, 12:26 PM EDT - 2 years ago

I-Mab (IMAB) Q2 2023 Earnings Call Transcript

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

Aug 17, 2023, 6:00 AM EDT - 2 years ago

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023

Aug 8, 2023, 8:00 AM EDT - 2 years ago

I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023

I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC

Jul 5, 2023, 8:00 AM EDT - 2 years ago

I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC

I-Mab Announces the Appointment of Raj Kannan as CEO

Jun 22, 2023, 8:00 AM EDT - 2 years ago

I-Mab Announces the Appointment of Raj Kannan as CEO

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023

May 25, 2023, 5:01 PM EDT - 2 years ago

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023

I-MAB Filed 2022 Annual Report on Form 20-F

May 1, 2023, 8:00 AM EDT - 2 years ago

I-MAB Filed 2022 Annual Report on Form 20-F

Chomo
Chomo Jul. 24 at 12:46 AM
$IMAB very tight but not volume at all
0 · Reply
Alexsandrab85
Alexsandrab85 Jul. 21 at 8:49 PM
$IMAB still holding 500 shares for dear
0 · Reply
Stocksman45
Stocksman45 Jul. 19 at 5:05 PM
$IMAB Complete Ownership? Thats great. I though biolabs had a piece of it. Next trial results has been moved up a couple of months to Q1 2026. With complete ownership, IMAB is a much more valuable target for aquisition or partnerships. "The deal structure is notably favorable - an upfront payment of only $1.8 million with $1.2 million in non-contingent payments through 2027, plus potential milestone payments up to $3.875 million. This represents a relatively modest investment to secure complete ownership of intellectual property that could become substantially more valuable if givastomig continues to show promising clinical results."
0 · Reply
Stocksman45
Stocksman45 Jul. 19 at 2:41 AM
$IMAB Bold positive move. Results of next trial sooner. All good. https://finance.yahoo.com/news/mab-strengthens-givastomig-intellectual-property-110000252.html
1 · Reply
jParkz
jParkz Jul. 15 at 12:30 AM
News out I-Mab to Present at the BTIG Virtual Biotechnology Conference https://marketwirenews.com/news-releases/i-mab-to-present-at-the-btig-virtual-biotechnology-c-6007643620724269.html $IMAB
0 · Reply
serfi
serfi Jul. 10 at 8:18 PM
$IMAB this is going to zero?
2 · Reply
JarvisFlow
JarvisFlow Jul. 9 at 11:00 AM
HC Wainwright & Co. updates rating for I-MAB ( $IMAB ) to Buy, target set at 7.
2 · Reply
JarvisFlow
JarvisFlow Jul. 9 at 11:00 AM
Needham updates rating for I-MAB ( $IMAB ) to Buy, target set at 5.
0 · Reply
LegendaryCharts
LegendaryCharts Jul. 9 at 9:34 AM
What is happening to APLM right now?! Seems like volume could be shifting in to APLM! This could be the next multi - day runner! APLM moves like a true nano nano floater! Show me some 50K buying candles and this could HALT UP and spike to 15+$ Some will buy now some will chase later! $NAOV $AUUD $IMAB $SNPX Update loading .
0 · Reply
Szilis793
Szilis793 Jul. 8 at 5:02 PM
$IMAB Exciting news ahead — a big breakthrough is coming soon for IMAB
1 · Reply
WellWorth
WellWorth Jul. 7 at 11:51 AM
$IMAB I'm new here and would like to take a position. What is expected tomorrow during the call?
1 · Reply
Stocksman45
Stocksman45 Jul. 6 at 5:07 PM
$IMAB Here is the IMAB link to the July 8th investor conference for the blockbuster Givastomig. New buyers. 12 month projections $5-7. https://lifescievents.com/event/vhywe958n43n/
0 · Reply
neangewo
neangewo Jul. 6 at 1:34 AM
$IMAB KOL webinar for Givastomig data 8 July, 2 PM, EST.
0 · Reply
SecondChances
SecondChances Jul. 2 at 11:45 PM
$IMAB if the results can replicate in larger studies, Giva has blockbuster written all over it.
0 · Reply
Tarde75
Tarde75 Jul. 2 at 3:20 PM
$IMAB I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
0 · Reply
Stocksman45
Stocksman45 Jul. 2 at 12:31 PM
$IMAB More news of success with Givastomig … https://finance.yahoo.com/news/mab-announces-publication-givastomig-monotherapy-200100780.html
0 · Reply
BullMrketsBack
BullMrketsBack Jun. 29 at 7:21 PM
China getting hot again, Ticker YJ should be on everyone's buy list. Bottom low float, setting up for a multi-day run. YJ-Company has 74M cash on hand, $14.80 cash per share, crazy numbers! Don't miss it bulls. $CTOR $SOND $IMAB $GVH
0 · Reply
StockScanners
StockScanners Jun. 28 at 2:42 AM
$IMAB Keep watch if this holds above 2.40
0 · Reply
FloatRaider
FloatRaider Jun. 27 at 5:46 PM
$IMAB Will surge soon. Calm before the storm ATER 300k+ short shares to be returned next week. News this week + Insiders just bought loads of shares. Management is cutting down cost for increasing profitability + launching new products & new market. 8$ PT
1 · Reply
AntoineChigurh
AntoineChigurh Jun. 27 at 5:41 PM
$CTOR $HYPD $GCTK $IMAB $INMB lowlife pumper all day
0 · Reply
topstockalerts
topstockalerts Jun. 27 at 4:39 PM
Top Gainers PT2 $INMB $CTOR $IMAB $HYPD $GCTK
0 · Reply
UnicornPicks
UnicornPicks Jun. 27 at 4:11 PM
Shared these free ideas $LCFY $TRNR $IMAB $CTOR this morning.
0 · Reply